Thompson Siegel & Walmsley’s Dr. Reddy's Laboratories RDY Stock Holding History

Thompson Siegel & Walmsley’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$11K	–	610
2022 Q1	$11K	Hold	1,000	–	–	﹤0.01%	538
2021 Q4	$13K	Hold	1,000	–	–	﹤0.01%	544
2021 Q3	$13K	Hold	1,000	–	–	﹤0.01%	616
2021 Q2	$15K	Hold	1,000	–	–	﹤0.01%	623
2021 Q1	$12K	Hold	1,000	–	–	﹤0.01%	621
2020 Q4	$14K	Hold	1,000	–	–	﹤0.01%	587
2020 Q3	$14K	Hold	1,000	–	–	﹤0.01%	556
2020 Q2	$11K	Hold	1,000	–	–	﹤0.01%	580
2020 Q1	$8K	Hold	1,000	–	–	﹤0.01%	576
2019 Q4	$8K	Hold	1,000	–	–	﹤0.01%	646
2019 Q3	$8K	Hold	1,000	–	–	﹤0.01%	662
2019 Q2	$7K	Hold	1,000	–	–	﹤0.01%	671
2019 Q1	$8K	Hold	1,000	–	–	﹤0.01%	607
2018 Q4	$8K	Hold	1,000	–	–	﹤0.01%	660
2018 Q3	$7K	Hold	1,000	–	–	﹤0.01%	702
2018 Q2	$6K	Hold	1,000	–	–	﹤0.01%	740
2018 Q1	$7K	Hold	1,000	–	–	﹤0.01%	720
2017 Q4	$8K	Hold	1,000	–	–	﹤0.01%	743
2017 Q3	$7K	Hold	1,000	–	–	﹤0.01%	747
2017 Q2	$8K	Hold	1,000	–	–	﹤0.01%	724
2017 Q1	$8K	Hold	1,000	–	–	﹤0.01%	714
2016 Q4	$9K	Hold	1,000	–	–	﹤0.01%	654
2016 Q3	$9K	Buy	+1,000	New	+$9.55K	﹤0.01%	647

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Thompson Siegel & Walmsley's RDY Position: Q2 2022 in Review

Thompson Siegel & Walmsley sold out of Dr. Reddy's Laboratories (RDY) in Q2 2022, closing a stake of 1,000 shares — an estimated $11K sold.

Thompson Siegel & Walmsley first reported a position in RDY in Q3 2016 and held it in 23 quarters. The position peaked at $15K in Q2 2021. 148 funds tracked by Wall St. Rank hold RDY as of Q2 2022.

Thompson Siegel & Walmsley reported no remaining Dr. Reddy's Laboratories position as of Q2 2022 after selling out during the quarter.
Thompson Siegel & Walmsley sold 1,000 Dr. Reddy's Laboratories shares in Q2 2022, an estimated $11K.
Thompson Siegel & Walmsley first reported a position in Dr. Reddy's Laboratories in Q3 2016 and held it in 23 quarters.
Thompson Siegel & Walmsley's Dr. Reddy's Laboratories position peaked at $15K in Q2 2021.
148 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2022, filed 22 Jul 2022.